EdiGene, Inc.

EdiGene, Inc.

IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Transfusion Dependent Beta-Thalassemia, TDT, (NCT04390971)
Sponsors:
Institute of Hematology and Blood Diseases Hospital
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine